Discovery, Implementation and Mentorship in Personalized Cardiovascular Pharmacotherapy

个性化心血管药物治疗的发现、实施和指导

基本信息

批准号：
10459553
负责人：
NITA A LIMDI
金额：
$ 12.04万
依托单位：
UNIVERSITY OF ALABAMA AT BIRMINGHAM
依托单位国家：
美国
项目类别：
财政年份：
2016
资助国家：
美国
起止时间：
2016-08-01 至 2026-07-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10459553
关键词：
ABCB1 gene Address African American Age American Anticoagulants Anticoagulation Atrial Fibrillation Award CYP2C19 gene CYP3A4 gene Candidate Disease Gene Cardiovascular Diseases Cardiovascular system Chronic Disease Clinical Clinical Research Computerized Medical Record Doctor of Philosophy Dose Enrollment Ensure Environmental Risk Factor Epidemiology European Foundations Funding Future Generations Genes Genetic Genetic Variation Genome Genomics Genotype Goals Grant Guidelines Heart failure Hemorrhage Institute of Medicine (U.S.)Knowledge Lead Leadership Medical Genetics Mentored Patient-Oriented Research Career Development Award Mentors Mentorship Mid-Career Clinical Scientist Award (K24)Monitor Oral Outcome Patient Recruitments Patients Performance Pharmaceutical Preparations Pharmacoepidemiology Pharmacogenetics Pharmacogenomics Pharmacotherapy Predictive Factor Preventive Productivity Prospective cohort Publications Publishing Renal function Research Research Personnel Resources Risk Risk Assessment Role Testing Therapeutic Therapeutic Intervention Time Training Training Programs Translational Research Translations United States National Institutes of Health Variant Warfarin Work acute coronary syndrome base cardiovascular disorder risk career clinical care clinical phenotype clinical practice clinical predictors collaborative environment comorbidity comparative cost effectiveness design effectiveness implementation study genetic information genetic predictors genome wide association study genomic predictors implementation efforts implementation science improved improved outcome individual variation individualized medicine patient oriented research percutaneous coronary intervention pharmacokinetics and pharmacodynamics population based precision drugs precision medicine programs response risk prediction sex skills supportive environment tool training opportunity translational framework venous thromboembolism

项目摘要

Abstract I have built a successful patient oriented research program focused on pharmacogenomics, pharmacoepidemiology, and chronic disease epidemiology with a focus on cardiovascular diseases. My research goal is to elucidate the role of clinical, environmental and genetic factors on variability in cardiovascular disease risk and response to medications and to use this information to tailor treatments, especially in patients with multiple comorbidities. The proposed award would enable me to continue mentoring while expanding my research program specifically incorporating implementation science tools to address key translational knowledge gaps. The new research proposed herein is builds on ongoing work to create unique and much needed patient oriented research (POR) training opportunities in cardiovascular pharmacotherapeutics and improvement in risk prediction by incorporating genomic information. My NIH grants along with the four new projects will form the basis for the mentee (MD, Pharm.D, and PhD) training. Mentorship aims expand the POR training opportunities for trainees. Mentees will lead the new projects, develop skills related to discovery and implementation, conduct analysis and publish original research. They will leverage this to propose new research as part of their NIH- K23 applications. PROJECT1 will elucidate the differential effect of sex and age on gene-hemorrhage association among anticoagulant users. PROJECT 2 will evaluate the influence of pharmacogenetic variants on Apixaban and Rivaroxaban pharmacokinetics and pharmacodynamics. PROJECT 3 will evaluate the performance of bleeding risk scores and the integration of genetics in risk prediction among patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI). PROJECT 4 will evaluate the influence of heart failure on outcomes among patients with ACS undergoing PCI. In the supportive and collaborative environment of UAB, this award will ensure that I continue to grow my research program expand to include hybrid implementation-effectiveness designs and build capacity in POR by mentoring junior investigators to build their own careers. The breadth and depth of the multiple NIH- funded institutional training programs, UAB’s CTSA and her leadership in UAB’s Translational Pharmacogenomics and Precision Medicine Institute will provide the resources and the foundation to advance discovery and implementation efforts to enable translation of research discoveries into clinical care.

抽象的我建立了一个成功的以患者为中心的研究项目，重点关注药物基因组学，药物流行病学和慢性病流行病学，重点是心血管疾病。研究目标是阐明临床、环境和遗传因素对变异的作用心血管疾病风险和对药物的反应，并利用这些信息来制定治疗方案，尤其是患有多种合并症的患者。拟议的奖项将使我能够在扩大我的研究计划的同时继续提供指导具体实施科学工具来解决关键的转化知识差距。本文提出的新研究建立在正在进行的工作的基础上，以创造独特且急需的患者心血管药物治疗和改善的定向研究（POR）培训机会通过整合基因组信息进行风险预测。我的 NIH 拨款以及四个新项目将构成受训者（医学博士、药学博士和博士）培训的基础。指导旨在扩展 POR 培训。受训者将有机会领导新项目，培养与发现和发展相关的技能。他们将利用这一点来提出新的建议。研究作为 NIH-K23 应用的一部分。 PROJECT1 将阐明性别和年龄对基因出血关联的不同影响项目 2 将评估药物遗传学变异对阿哌沙班和抗凝剂使用者的影响。项目 3 将评估利伐沙班的药代动力学和药效学性能。急性冠心病患者出血风险评分以及遗传学在风险预测中的整合项目 4 将评估心力衰竭对接受 PCI 的 ACS 患者结局的影响。在 UAB 的支持和协作环境中，这个奖项将确保我继续成长研究计划扩大到包括混合实施-有效性设计和 POR 能力建设通过指导初级研究人员建立自己的职业生涯的广度和深度。资助机构培训计划、UAB 的 CTSA 以及她在 UAB 转化中的领导力药物基因组学和精准医学研究所将为发现和实施工作，使研究发现能够提前转化为临床关心。